check_circleStudy Completed

Rhinitis, Allergic

A study to evaluate changes in nasal airflow of Loratadine/Pseudoephedrine tablet and Fluticasone Propionate nasal spray in subjects following allergen exposure

Trial purpose

The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms.

Key Participants Requirements

Sex

All

Age

18 - 65 Years

Trial summary

Enrollment Goal
82
Trial Dates
February 2018 - May 2018
Phase
Phase 4
Could I Receive a placebo
Yes
Products
Claritin-D® (Loratadine + Pseudoephedrine sulfate, BAY818725)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Kingston General HospitalKingston, K7L 2V7, Canada

Primary Outcome

  • Average percent change in PNIF (Peak Nasal Inspiratory Flow) from 0 to 4 hours after dosing
    date_rangeTime Frame:
    Up to 4 hours

Trial design

A Double-Blind Placebo-Controlled Crossover Study to Evaluate Objective Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure in an Environmental Exposure Unit
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
N/A
Assignment
Crossover Assignment
Trial Arms
4